Expansion of pharmacist clinical services to optimize the management of immune checkpoint inhibitor toxicities

Abstract

Introduction

The development of immune checkpoint inhibitors has revolutionized cancer treatment and is now a part of the treatment paradigm for several malignancies. Although immune checkpoint inhibitors are generally well tolerated, treatment is associated with immune-related adverse events, some serious and potentially life threatening. Early identification and prompt appropriate management of immune-related adverse events are crucial to prevent morbidity and mortality. The complexity and severity of immune-related adverse events require interdisciplinary collaboration to optimize care. Patient and caregiver education and continued communication between patients and members of the oncology care team are vital for timely recognition and successful management of immune-related adverse events. The objective of this program is to provide a proof of concept; a pharmacist-led immune checkpoint inhibitor management program will increase early recognition and management of immune-related adverse events through patient and caregiver education and proactively assessing patients for toxicities.

Methods

At the University of Wisconsin Carbone Cancer Center, we developed and implemented a pharmacist-driven program, referred to as the immune checkpoint inhibitor program, which aimed to ensure patient and caregiver education and continuous monitoring of immune-related adverse events. This program utilized pharmacist–patient encounters to improve patient and caregiver education and follow-up monitoring. The design and implementation are detailed. Pharmacist interventions and patient outcomes were evaluated.

Results

At interim analysis, 47 patients were enrolled in the program and pharmacists completed 34 interventions on 26 patients. Pharmacists are well positioned to educate patients and caregivers on immune checkpoint inhibitor therapy and provide proactive monitoring to detect immune-related adverse events. We hypothesize that the interventions made by pharmacist may lead to earlier recognition and treatment of immune-related adverse events.

Keywords

Immune checkpoint inhibitor toxicities immune-related adverse events management of immunotherapy toxicities pharmacy clinical services

Get full access to this article

View all access options for this article.

References

Pazdur

. Biologics license application for ipilimumab, Wallingford, CT: Services DoHaH, 2011.

Hodi

O'Day

McDermott

et al.

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–723.

Yervoy (2011) (ipilimumab) (package insert). New Jersey: Bristol-Myers Squibb.

Opdivo (2018) (nivolumab) (package insert). New Jersey: Bristol-Myers Squibb.

Keytrude (2017) (pembrolizumab) (package insert): New Jersey: Merck.

Tecentriq (2016) (atezolizumab) (package insert): California: Genetech, Inc.

Bavencio (2017) (avelumab) (package insert). Massachusetts: EMD Serono, Inc.

Imfinzi (2017) (durvalumab) (package insert). Delaware: AstraZeneca Pharmaceuticals LP.

Spain

Diem

Larkin

. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 2016; 44: 51–60.

10.

Larkin

Chiarion-Sileni

Gonzalez

et al.

Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23–34.

11.

Haanen

Carbonnel

Robert

et al.

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28: iv119–iv142.

12.

Champiat

Lambotte

Barreau

et al.

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016; 27: 559–574.

13.

Brahmer

Lacchetti

Schneider

et al.

Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 14: 247–249.

14.

Akel

Anouti

Tfayli

. Late-onset inflammatory bowel disease-like syndrome after ipilimumab therapy: a case report. Case Rep Oncol 2017; 10: 456–461.

15.

Dasanu

Jen

Skulski

. Late-onset pericardial tamponade, bilateral pleural effusions and recurrent immune monoarthritis induced by ipilimumab use for metastatic melanoma. J Oncol Pharm Pract 2017; 23: 231–234.

16.

Mandala

Merelli

Indriolo

et al.

Late-occurring toxicity induced by an immune checkpoint blockade in adjuvant treatment of a stage III melanoma patient. Eur J Cancer 2018; 95: 130–132.

17.

Villadolid

Amin

. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res 2015; 4: 560–575.

18.

Puzanov

Diab

Abdallah

et al.

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017; 5: 95.

19.

Shank

Schwartz

Fortner

et al.

Advances in oncology pharmacy practice. Am J Health Syst Pharm 2015; 72: 2098–2100.

20.

Renna C, Dow E, Bergsbaken J, Leal T. Expansion of pharmacy services to optimize the management of immune-related adverse events. Denver, CO. March 21, 2018. In: HOPA Annual Conference 2018.

21.

Services UDoHaH. Common terminology criteria for adverse events (CTCAE) version 4.0, Bethesda, MD: National Cancer Institute, 2009.

22.

Reynolds

Cohen

Durbin

et al.

Inpatient admissions related to immune-related adverse effects (irAE) among patients treated with immune checkpoint inhibitors for advanced malignancy: A tsunami is coming, but are we ready?. J Clin Oncol 2018; 36: 127.